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Fifty-four patients underwent total hepatectomy and liver re-
placement in the presence of a primary liver malignancy. In 13 
recipients in whom the hepatic tumors were incidental to some 
other end stage liver disease, recurrence was not seen and 12 of 
the 13 patients are alive after 4 months to 151/2 years. In contrast, 
tumors recurred in 3 of every 4 patients who received liver re-
placement primarily because of hepatic malignancies that could 
not be resected by conventional techniques of subtotal hepatec-
tomy and who lived for at least 2 months after transplantation. 
The most encouraging results were in patients with the fibro-
lamellar hepatocellular carcinomas that grow slowly and metas-
tasize late, but even with this lesion, the recurrence rate was 
57%. In future trials, additional effective anticancer therapy will 
be needed to improve the results of liver transplantation for pri-
mary liver malignancy, but what an improved strategy should 
be has not yet been defined. 
I N THE EARLY TRIALS of liver transplantation, an un-
equivocal indication for liver replacement was thought 
to be a primary hepatic malignancy that could not be 
removed by conventional techniques of subtotal hepatic 
resection. Enthusiasm for the approach was dampened in 
several major centers by the high recurrence rates of orig-
inal malignancies. I- 4 Nevertheless, the impulse to treat 
malignant tumors by liver transplantation is still present 
today because of: (1) the lack of other effective therapy; 
(2) rare examples of cure of malignancy by total hepatec-
tomy and liver replacement; and (3) the improved overall 
survival after liver transplantation with cyclosporine-ste-
roid therapy in recent years. 
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From the Department of Surgery, University of Pittsburgh 
School of Medicine, Pittsburgh, Pennsylvania 
A recent review of our 54 patients who received ortho-
topic liver transplantation in the presence of primary he-
patic malignancy has provided a more definitive idea of 
the role of liver replacement in cancer therapy. 
Case Material and Methods 
During the 22-year period of March 1, 1963, to March 
3, 1985, 500 patients with various liver diseases received 
orthotopic liver transplants. Treatment was provided at 
the University of Colorado Health Sciences Center until 
the end of 1980 and at the University Health Center of 
Pittsburgh thereafter. Fifty-four (10.8%) of the 500 recip-
ients had transplantation in the presence of a primary 
hepatic malignancy. They were divided into two groups 
for analysis. 
Group I consisted of 13 patients who had liver replace-
ment primarily to treat an endstage non-neoplastic liver 
disease, but who were found to have a coincidental pri-
mary hepatic malignancy either before transplantation or 
after examination of the excised whole liver (Table 1). 
The tumors could have been totally removed by partial 
hepatectomy, if the liver had not been so seriously dis-
eased. In contrast, Group II consisted of 41 patients whose 
sole or principal reason for liver replacement was a ma-
lignancy that could not be removed by subtotal hepatec-
tomy (Table 2). The patients in both Groups I and II were 
stratified according to whether immunosuppression was 
with azathioprine, corticosteroids, and antilymphocyte 
globulin (ALG), as in Subgroup A, or, after March 1980, 
with cyclosporine and corticosteroids, as in Subgroup B. 
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TABLE I. Fate 003 Patien/s Who Had Liver Transplantation Primaril)'!i" Endstage Non-neoplastic Liver Disease, BUI Who 
Had Incidental Primary Liver Malignancies as well (Group I) 
Patient 
Age 
(Yr.) Sex 
Primary Indication for 
Transplant 
Nature of Liver 
Malignancy Survival 
Tumor 
Recurrence 
Group I-A: Immunosuppression with Azathioprine + Prednisone + ALG 
OT 33 3 F Biliary atresia Hepatocellular carcinoma Alive 15'13 yrs. No 
OT 80 7 F Biliary atresia Hepatocellular carcinoma Died I day after surgery No residual 
tumor at 
autopsy 
No OT 142 5 F Alpha-I-antitrypsin deficiency 
disease 
Group I-B: Immunosuppression with Cyclosporine + Prednisone 
OT 198 47 F Alpha-I-antitrypsin deficiency 
disease 
Hepatoblastoma Alive over 7'/6 yrs. 
Hepatocellular carcinoma Alive 3'13 yrs. No 
OT 206 
OT 222 
OT 288 
OT 344 
OT 356 
OT 379 
OT400 
OT475 
OT483 
2 
7 
21 
52 
3 
8 
3 
9 
45 
F 
F 
F 
M 
F 
F 
M 
M 
F 
Tyrosinemia 
Sea-blue histiocyte syndrome 
Tyrosinemia 
Alcoholic cirrhosis 
Tyrosinemia 
Biliary atresia 
Tyrosinemia 
Alagille's syndrome 
Cirrhosis, HBsAg-pos, 
Hepatocellular carcinoma 
Hepatocellular carcinoma 
Hepatocellular carcinoma 
Hepatocellular carcinoma 
Hepatocellular carcinoma 
Hepatocellular carcinoma 
Hepatocellular carcinoma 
Hepatocellular carcinoma 
Hepatocellular carcinoma 
Alive 3'h yrs. 
Alive 3'/. yrs. 
Alive 2 yrs. 
Alive 16 mos. 
Alive 15 mos. 
Alive 12 mos. 
Alive II mos. 
Alive 4 mos. 
Alive 4 mos. 
No 
No 
No 
No 
No 
No 
No 
No 
No 
The patient identification number (OT), age, sex, di-
agnosis, survival as of April 15, 1985, tumor recurrence, 
and main cause of death for all patients are listed in Tables 
1 and 2. The recipient ages ranged from 2 to 68 years 
(mean: 30). There are 22 males and 32 females. There 
were 37 hepatocellular carcinomas (HCC), of which seven 
were the fibrolamellar variant. The other tumors were 
eight bile duct carcinomas (Klatskin tumors), three epi-
theloid hemangioendothelial sarcomas, two cholangio-
carcinomas, and one each hepatoblastoma, angiosarcoma, 
adenocarcinoma of unknown primary site, and sarcoma 
of undetermined cell type (Table 3). 
Results 
Residual Tumor 
No patients with primary liver malignancy who un-
derwent liver transplantation were known preoperatively 
to have extrahepatic involvement. However, three patients 
of Group II (OT 114,305, and 473) were left with gross 
residual neoplasm at the time of transplantation. One (OT 
114) with sarcoma of undetermined cell type had fine 
metastases to the lung and peritoneum. She is still alive 
and well without any signs of tumor regrowth more than 
8 years later. Another woman (OT 305) with hemangio-
sarcoma had metastases to the lungs and omentum at the 
time of transplantation. When she died 3 months after 
operation as the result of pneumonia and liver graft failure, 
her autopsy also revealed metastases to the bone marrow. 
The third patient (OT 473) had adenocarcinoma of un-
known primary site with metastases to abdominal lymph 
nodes at the time of transplantation. This patient is alive 
and well without any clinical and radiological evidence 
of tumor enlargement or further metastasis in the fifth 
post-transplant month. 
Eleven other patients in Group II (OT 2,3,4,5,6, 17, 
25,79, 185,234,251) died within 2 months from various 
complications of liver transplantation. Before operation, 
all 11 were thought to be free of extrahepatic tumor. At 
autopsy, only one patient (OT 4) had gross or histopath-
ologic evidence of residual neoplasm. This patient, who 
survived only 5 days after liver transplantation, had met-
astatic cholangiocarcinoma in the lungs, vertebra, kidneys, 
and some abdominal lymph nodes. The remaining 10 
patients were tumor free insofar as this could be deter-
mined from complete post-mortem examination, indi-
cating that screening for candidacy had been grossly ac-
curate in the great majority of cases. 
Tumor Recurrence 
With incidental malignancies, In Group I, 12 of the 13 
patients whose excised livers contained incidental primary 
liver malignancies are still alive and well without evidence 
of tumor recurrence after 4 months to more than 15 years 
(median: 16 months) (Table 1). Eleven of the 12 surviving 
patients, as well as the patient who died, had hepatocellular 
carcinoma. The other recipient had a hepatoblastoma, 
With un resectable malignancies, In Group II, 30 of the 
41 patients whose main reason for liver transplantation 
was primary liver malignancy, survived for at least 2 
months after transplantation and thus became available 
for meaningful observations about recurrence. The 30 re-
cipients included the three (OT 114, 305,473) who were 
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found at transplantation to have extrahepatic involve- are projected at 68% and 25% (Fig. 2). At t~eK prese?t 
ment, as described in the preceding section. The other 27 time, only 10 (48%) of the original 21 recIpIents m 
(Table 4) were considered to have all gross tumor removed Subgroup B are still alive after 4 months to 3% years. One 
of the survivors (at 4 months) is a patient who had tumor by total hepatectomy. f I 
In 20 (74%) of the 27 patients who were made poten- positive regional lymph nodes at the time 0 transp an-
tially tumor free by transplantation, the original tumor tation, and four others are living with known recurrences. 
recurred after 1 to 42 months (median: 8 months). Non-
fibrolamellar hepatocellular carcinoma recurred in nine 
(82%) of 11 patients, all within a year (median: 4 months) 
(Table 4). Recurrence offibrolamellar hepatocellular car-
cinoma also was seen in four (57%) of seven patients (Ta-
ble 4) but always after 1 year (median: 15 months). Four 
of the five bile duct carcinomas recurred, two before and 
two after the I-year mark; the exceptional patient who 
did not have a recurrence died of other causes only 2 
months after the operation. Two of the three epitheloid 
hemangioendothelial sarcomas recurred within a year. 
One patient with cholangiocarcinoma developed a tumor 
recurrence in the 15th postoperative month. 
Patient Survival 
The overall results after liver transplantation have im-
proved greatly since the introduction of cyclosporine-ste-
roid therapy in March 1980.5 Since this time, the survival 
expectation at 1 postoperative year and each year there-
after for at least 5 years has more than doubled compared 
to that previously obtained with azathioprine, prednisone, 
and ALG (Fig. 1). The projected actuarial 5-year survival 
in all patients treated since 1980 is 63%. 
Group I tumor patients. Twelve of the 13 patients who 
had incidental hepatic malignancies are still alive from 4 
months to 15 112 years after surgery (Table 1). The only 
mortality was of a patient treated with azathioprine, pred-
nisone, and ALG (Subgroup A), who died on the first 
postoperative day. The two other patients of Subgroup A, 
as well as all 10 of the recipients treated with cyclosporine 
and steroids (Subgroup B), are living (Table 1). 
Group II tumor patients. Of the 20 patients of Subgroup 
A who were treated with azathioprine, prednisone, and 
ALG, 13 (65%) had died by the end of the first 6 months. 
At the end of the year, only 6 (30%) remained alive, of 
whom all but one have subsequently died (Fig. 2). The 
single survivor, now 8% years after surgery, had a sarcoma 
of undetermined cell type with peritoneal and pulmonary 
metastases at the time of transplantation. 
The patients of Subgroup B had greatly improved early 
postoperative results, with a 6-month actuarial survival 
of more than 80%. This reflected the better overall prog-
nosis for early recovery using cyclosporine-steroid therapy. 
However, after the half-year mark, survival continued to 
decline, primarily because of the recurrent disease, as will 
be described in the next two sections. The actuarial l-
and 3-year survivals in the cyclosporine-treated patients 
Main Causes oJGroup II Patient Deaths 
Thirty of the 41 patients whose principal reason for 
liver transplantation was the presence of a primary liver 
malignancy had died before April 15, 1985. Twenty-one 
of the 30 deaths were within 1 year after transplantation, 
and five of the 21 deaths were directly caused 5 to 12 
months after transplantation by tumor recurrence. The 
rest of the deaths during the first year were due to non-
neoplastic complications such as graft failure or infections, 
or both (Table 2); the majority of these cases were from 
our early experience before 1970. Of the nine deaths that 
occurred a year or more after transplantation, eight were 
caused directly by tumor recurrence (Table 2). Thus, the 
shape of the life survival curves both before and after the 
introduction of cyc1osporine was dominated from the fifth 
month onward by the deadly effects of tumor recurrence. 
Histology versus Survival in 41 Group II Patients 
Of the seven patients with fibrolamellar hepatocellular 
carcinoma, one, who is free of tumor after 5 months, has 
too short a follow-up to merit comment. The other six 
lived for at least 1 year and were thought to be free of 
tumor at the end of that time. Subsequently, metastases 
developed in four of the six recipients, of whom two died. 
The two patients who are living with known recurrent 
fibrolamellar neoplasms have been followed for 17 and 
36 months, and one has seemed to respond to adriamycin 
and other chemotherapeutic agents. 
In contrast, patients with nonfibrolamellar hepatocel-
lular carcinomas had earlier and more lethal metastases. 
Of 25 such recipients, two who are alive after 5 and 6 
months have too short a follow-up to be discussed. Of the 
other 23, five lived for as long as 1 year, at which time all 
but one had known metastases. The four who had me-
tastases at 1 year died 12 to 17 months after transplan-
tation; the fifth patient remains tumor free after 15 
months. Thus, the conventional hepatomas carried a far 
poorer prognosis than the fibrolamellar variant. 
Of the 16 patients with malignancies other than he-
patocellular carcinoma, six lived more than 1 year, and 
one (OT 473) is alive in the fourth month (Table 4). 
Location oj Recurrences 
The grafted liver and the lung were the two organs most 
commonly affected by tumor recurrence (Table 2). The 
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TABLE 2. Fate 0(41 Patients Who Had Liver Transplantation Because of Primary Liver Malignancy 
Timing and 
Location of First Organs 
Recurrence or Ultimately 
Age Primary Indication for Coexisted (Location of Treatment for Involved by Main Cause of 
Patient (Yr.) Sex Transplant Liver Disease Residual Tumor) Recurrence Tumor Survival Death 
Group II-A: Immunosuppression with Azathioprine + Prednisone + ALG 
OT 2 48 M Hepatocellular Post-necrotic (No residual tumor) Died < I mo. Pulmonary emboli, 
carcinoma cirrhosis sepsis 
OT 3 68 M Bile duct cancer (No residual tumor) Died < I mo. Sepsis, pulmonary 
(Klatskin tumor) emboli, GI-
bleeding 
OT4 52 M Cholangiocarcinoma Post-necrotic (Residual: bone, Died < I mo. Graft failure, sepsis, 
cirrhosis lung, kidney, pulmonary 
Iymphnodes) emboli 
aT 5 29 F Hepatocellular Post-necrotic (No residual tumor) Died < I mo. Sepsis, bile 
carcinoma cirrhosis peritonitis, graft 
failure 
OT 6 29 M Hepatocellular (No residual tumor) Died < I mo. Graft failure, sepsis 
carcinoma 
aT 8 2 F Hepatocellular 3 mos.; lungs Chemotherapy, Lungs, liver, Died/14 mos. Carcinomatosis 
carcinoma radiation, brain, other 
debulking abdominal 
organs 
aT 14 16 F Hepatocellular 13 mos.: liver, None Liver, diaphragm, Died/IS mos. Carcinomatosis, 
carcinoma-FL· diaphragm, pancreas, infection after 
retroperitoneum peritoneum retransplant 
aT IS 43 M Hepatocellular Post-necrotic 2 mos.; lungs None Lungs, liver. Died/l2 mos. Carcinomatosis 
carcinoma cirrhosis diaphragm 
OTI7 24 F Hepatocellular (No residual tumor) Died/2 mos. Pneumonitis 
carcinoma 
OT23 IS M Hepatocellular I mo.: lungs None Lungs, liver, Died/5 mos. Carcinomatosis 
carcinoma brain, 
peritoneum 
aT 25 45 M Hepatocellular (No residual tumor) Died/2 mos. Bile peritonitis, 
carcinoma sepsis, graft 
failure 
OT 26 II F Hepatocellular Biliary atresia 3 mos.: lungs None Lungs Died/3 mos. GI-bleeding, sepsis 
carcinoma 
aT 45 S3 M Epitheloid 2 mos.: lungs, liver None Lungs, liver, Died/3 mos. Sarcomatosis 
hemangioendothelial brain, spleen, 
sarcoma kidneys 
aT 78 48 F Bile duct cancer 21 mos.: liver, bile Radiation Liver, bile duct Died/25 mos. Tumor recurrence 
(Klatskin tumor) duct 
OT 79 60 M Bile duct cancer (N a residual tumor) Died < 1 mo. Graft failure due to 
(Klatskin tumor) bile duct 
obstruction 
aT 90 41 M Bile duct cancer 42 mos.: bile duct radiation Bile duct, liver, Died/54 mos. Tumor recurrence 
(Klatskin tumor) duodenum 
aT 102 51 F Bile duct cancer None Died/3 mos. Candidiasis, brain 
(Klatskin tumor) abscess 
aT III 9 F Hepatocellular Tyrosinemia None before Micrometastasis Died/3 mos. Portal vein 
carcinoma autopsy in lung and thrombosis, 
para-aortic death during 
nodes at retransplant 
autopsy 
aT 114 27 F Sarcoma of (Fine intra- None No recurrence Alive/8 2h yrs. 
undetermined cell abdominal and over 8 yrs. 
type pulmonary 
metastasis at 
transplant) 
aT 121 32 F Hepatocellular None None None Died/6 mos. Brain injury after 
carcinoma falling, inanition, 
pneumonia 
Group II-B: Immunosuppression with Cyc1osporine + Prednisone 
OTI72 24 M Hepatocellular 30 mos.; pelvis None Pelvis, rectum. Died/33 mos. Carcinomatosis, 
carcinoma-FL' bladder, pulmonary 
peritoneum emboli, 
pulmonary 
abscess 
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TABLE 2. (Continucd) 
Timing and 
Location of First Organs 
Recurrence or Ultimately 
Age Primary Indication for Coexisted (Location of Treatment for Involved Main Cause of 
Patient (Yr.) Sex Transplant Liver Disease Residual Tumor) Recurrence by Tumor Survival Death 
OT 176 33 F Bile duct cancer Sclerosing 10 mos.; bile duct Radiation Bile duct, liver, Died/12 mos. Tumor recurrence 
cholangitis jejunum 
OT 185 56 M Bile duct cancer (No residual tumor) Died/l mo. Sepsis, graft failure 
(Klatskin tumor) 
OT 194 26 M Hepatocellular None Alive/3'!4 yrs. 
carcinoma·FL * 
OT 200 27 M Bile duct cancer 6 mos.; skin Radiation Skin, bile Died/8 mos. Tumor recurrence 
(Klatskin tumor) duct, liver, 
peritoneum 
OT 227 53 M Hepatocellular Post-necrosis 12 mos.; bone None Bone, no autopsy Died/14 mos. Myocardial 
carcinoma cirrhosis infarction 
OT 231 23 F Hepatocellular 13 mos.; lungs Chemotherapy Lungs Alive/3 yrs. 
carcinoma-FL * 
OT 234 24 F Hepatocellular (No residual tumor) Died/2 mos. Ischemic colon 
carcinoma necrosis, sepsis, 
graft failure 
OT 251 52 F Hepatocellular Thorotrast (No residual tumor) Died/2 mos. Candida sepsis, 
carcinoma liver graft failure 
OT 260 36 F Cholangiocarcinoma 15 mos.; liver Radiation Liver, lungs, Died/20 mos. Carcinomatosis 
bile duct, 
peritoneum 
OT 300 25 M Hepatocellular None Alive/22 
carcinoma-FL * mos. 
OT 305 35 F Hemangiosarcoma (Residual: lungs. Lungs, Died/3 mos. Pneumonia, graft 
peritoneum) peritoneum failure 
bone marrow 
OT 316 33 F Epitheloid None Alive/20'/' 
hemangioendothelial mos. 
sarcoma 
OT 322 26 F Epitheloid 12 mos.; liver Chemotherapy, Liver, lungs Died/16 mos. Tumor recurrence 
hemangioendothelial radiation 
sarcoma 
OT 324 29 F Hepatocellular 5 mos.: bone Chemotherapy Bone, liver, Died/l 7 mos. Carcinomatosis 
carcinoma lungs, lymph 
nodes 
OT 338 24 M Hepatocellular 16 mos.; liver, lung Alive/17 
carcinoma-FL· mos. 
OT 351 32 F Hepatocellular None Alive/I 5 
carcinoma mos. 
OT454 M Hepatocellular Tyrosinemia 4 mos.; liver Chemotherapyt Alive/6 mos. 
carcinoma 
OT462 51 M Hepatocellular Post-necrotic 4 mos.; liver, lung Chemotherapyt Alive/5 mos. 
carcinoma cirrhosis, 
HBsAg+ 
OT466 47 F Hepatocellular None Chemotherapyt Alive/5 mos. 
carcinoma-FL· 
OT473 54 F Adenocarcinoma of (Residual: Alive/4 mos. 
undetermined abdominal lymph 
primary site nodes 
• Fibrolamellar hepatocellular carcinoma. t Chemotherapy started before clinical evidence of recurrent tumor. 
liver was ultimately involved by recurrent tumor in 12 later developed metastases. The liver was the first site of 
cases. Other locations within the abdomen such as ab- recurrence in eight cases, the lung in six cases, both the 
dominallymph nodes and the peritoneum were affected liver and the lung simultaneously in two cases, the bone 
in 13 cases. The lung became involved in 11 cases, and in two cases, and the skin and the pelvic peritoneum in 
the brain and the bones in three cases each. one case each. 
The first locations of tumor recurrence and the organs 
ultimately involved by tumors were examined in the 20 Discussion 
patients of Group II (Table 2) who were rendered poten- The most encouraging aspect of this experience was the 
tially tumor free at the time of transplantation but who almost uniform survival of patients of Group I whose 
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TABLE 3. Histological Diagnosis 0/54 Primary Liver Malignancies 
I-A l-B II-A II-B Total 
Hepatocellular carcinoma 2 10 12 13 37 
(Nonflbrolamellar type) (2) (10) (II) (7) (30) 
(Fibrolamellar type) (0) (0) (I) (6) (7) 
Bile duct cancer 0 0 5 3 8 
Epitheloid hemangio-
endothelial sarcoma 0 0 1 2 3 
Cholangiocarcinoma 0 0 I 1 2 
Hepatoblastoma I 0 0 0 
Angiosarcoma 0 0 0 I 
Sarcoma of undetermined 
cell type 0 0 0 
Adenocarcinoma of 
unknown primary 
site 0 0 0 
Total 3 10 21 20 54 
otherwise diseased livers also contained incidental hepa-
tomas or, in one instance, a hepatoblastoma. The fact 
that none of these patients developed a recurrence during 
the 4 months to 15 11z years of follow-up proved that the 
mere presence of a hepatic malignancy is not an absolute 
contraindication to transplantation. 
Nevertheless, there was a tumor recurrence rate of74% 
in the patients of Group II who had neoplasms that were 
the fundamental reason for the total hepatectomy and 
transplantation and who survived for at least 2 months. 
It is possible that the high recurrence rate in Group II 
recipients merely reflected the advanced development of 
the neoplasms by the time a decision was made to attempt 
therapy with transplantation. An alternative and not nec-
essarily mutually exclusive explanation is that the im-
munosuppression necessary to prevent graft rejection may 
actually have expedited the growth of residual nests of 
cells left after the total hepatectomy, as was suggested a 
number of years ago l and supported by many recent in-
vestigations host factors promoting metastases.6- 8 The 
tendency of the metastases from hepatic malignancies to 
come back to the liver grafts has been noted before. 1,2 
Of all the tumor types for which experience has been 
accumulated so far, the fibrolamellar hepatocellular car-
cinoma has emerged as the best for treatment with trans-
TABLE 4. Tumor Recurrenee in 27 Patients of Group II 
No. Recurred 
No. No. Less Than 
Cases Recurred I Yr. 
Hepatocellular carcinoma 18 13 (72%) 9 
(Nonfibrolamellar type) II 9 (82%) 9 
(Fibrolamellar type) 7 4 (54%) 0 
Bile duct cancer 5 4 (80%) 2 
Epitheloid hemangio-
endothelial sarcoma 3 2 (67%) 2 
Cholangiocarcinoma I I (100%) 0 
Total 27 20 (74%) 13 
PERCENT SURVIVAL 
100% 
90% ~;---_ 
~: 1\"" .. " 
60% I \ 
50X '*-----
40% -----,.. _____ _ 
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0% l ~--~--~-~I 
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YEARS 
FIG. l. Survival (actuarial) of all cyclosporine-treated, comtJared to sur-
vival (actuarial) of all azathioprine-treated, liver transplant recipients. 0 
Cyclosporine group, 1980-1985 (n = 330); X Azathioprine group, 1963-
1980 (n = 170). 
plantation, This hepatoma variant, which was originally 
recognized by Edmondson9 and Peters, IO is known to be-
have less aggressively than most other malignant hepatic 
neoplasms, including the more common kind of hepa-
tocellular carcinoma. I 1-13 Although four of our seven pa-
tients with fibrolamellar hepatomas developed metastases, 
these tended to appear late and to grow relatively slowly. 
One of our patients with recurrence is in very good health 
2 years after multiple pulmonary metastases were first 
proved. 
With all other kinds of tumors, including the rest of 
the hepatocellular carcinomas, metastases have tended to 
appear early and to lead to death promptly. The prognosis 
with conventional hepatocellular carcinomas has been 
grim. Similarly, none of our patients with proximal duct 
cell carcinomas (Klatskin tumors) has been "cured," and, 
to our knowledge, this has not been accomplished in any 
other center. 
It has been tempting during the acquisition of this ex-
perience to conclude that liver replacement for malignant 
hepatic neoplasms is conceptually unsound, except for 
fibrolamellar hepatomas, and to abandon such efforts. 
PERCENT SURVIVAL 
I::: K--
:: I \'" 
::: [ \. 
40% 
30% 
20% 
10% 
OX 
0.2J 0.5 2 
YEARS 
FIG. 2. Survival rates for Group II-B patients (cyclosporine-treated) 
compared to Group II-A (azathioprine-treated) patients. X Group II-A 
(n = 20); 0 Group II-B (n = 21). 
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However, arrest and control of the malignant process have 
been accomplished under some ofthe least likely circum-
stances, as with the woman who had pulmonary and peri-
toneal seeding from a sarcoma at the time of transplan-
tation, the recipient with epitheloid hemangioendothelial 
sarcoma, and the patient with a conventional hepatoma. 
There has been no identifiable reason why the patients 
were spared recurrence and why the others were not. 
Liver transplantation will have to be tied to some other 
kind of therapeutic effort in future trials. The usual ap-
proach of giving adjuvant chemotherapy will not be good 
enough, as was shown in two of our recent patients with 
nonfibrolamellar hepatocellular carcinomas who devel-
oped metastases within a few months in spite of very ag-
gressive prophylactic treatment with adriamycin and other 
chemotherapeutic agents. Huber et al. 14 have described a 
novel approach in which two patients with metastatic liver 
disease had liver replacement as well as total body irra-
diation, chemotherapy, and bone marrow transplantation. 
One of their recipients whose original disease was a car-
cinoma of the breast was alive 3 years later after liver 
replacement and was free of tumor. I 5 
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DISCUSSION 
DR. PAUL RUSSELL (Boston, Massachusetts): All of us know that the 
Pittsburgh experience is unique, impressive, and, from what we have 
heard today, quite helpful. 
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The question is clearly whether we can better identify patients whose 
tumors are still confined to the liver. My questions to Dr. Iwatsuki are: 
What place, if any, does he think that preliminary exploration of the 
abdomen has? That is, should a "first look" with careful evaluation of 
lymph-node spread always be done? Also, are there any other diagnostic 
measures we might use in selecting patients with liver tumors who will 
most benefit from transplantation? 
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me to think of two things. 
Number one, you suggest that further chemotherapy will be necessary. 
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DR. JAMES H. FOSTER (Farmington, Connecticut): Dr. Iwatsuki, can 
you telI us anything about liver transplantation for secondary or metastatic 
cancer? 
DR. SHUNZABURO IWATSUKI (Closing discussion): Thank you very 
much, Dr. Russell. To answer your question as to how to select the 
patients, the way we usually handle the cancer patient for transplant is 
that we set up liver transplantation for two patients; the first patient, 
who is known to have a malignancy, and the second patient, who is 
known to have a benign disease. We start the operation earlier than the 
usual time and explore the cancer patient first. If the patient has extra-
hepatic involvement of the tumor, we stop the procedure there and call 
for the second patient. 
Answering the question of Dr. O'Leary, as I mentioned briefly during 
the presentation, we have tried chemotherapy after transplant before the 
recurrence. Adriamycin® was used in a pretty heavy dose in a short 
period of time for a few patients with hepatomas. Two patients who had 
hepatoma suffered a recurrence within 3 months in spite of the che-
motherapy. Therefore, we need more effective chemotherapeutic agents, 
or something else has to be added to liver replacement. 
Answering the question of Dr. Foster, we have not done any trans-
plantation for the patient with secondary metastasis. The Cambridge 
group and the Hanover group tried in several patients with metastatic 
liver malignancy, and they all died in 1 year with aggressive metastasis. 
Answering the question of whether the liver tumor after transplant is 
actually a recurrence or a de novo tumor, we do not know it for sure, 
but histologic characteristics of the recurrent tumor were quite similar 
to the original tumor that the recipient had before transplant, and there 
was almost always extrahepatic involvement by the time liver tumor 
was c1inicalIy detected. 
